We are supporting Cardiff University’s European Cancer Stem Cell Research Institute with ground-breaking work they are doing on finding new therapies for a particularly aggressive form of breast cancer. The Institute is working on research into a form of breast cancer called ‘triple negative breast cancer’ or TNBC. This tends to be more aggressive and cannot be treated with hormonal therapy or trastuzumab, a common breast cancer treatment. Researchers at the Institute have found a ‘molecular switch’ called LYN which exists at high levels in TNBC. It is particularly active in TNBC that develops in patients with a defective BRCA1 breast cancer gene. In the laboratory, the researchers have found that BRCA1-TNBC cancer is very sensitive to blocking LYN and is killed by this approach. More needs to be found out about the physical properties and biology of LYN so that compounds can be developed that could be used in patients.
We are supporting the European Cancer Stem Cell Research Institute by helping to fund studies of this ‘molecular switch’, which will form the basis of the development of new therapies for breast cancer patients.
Breast Cancer Research Aid visited European Cancer Stem Cell Research Institute, Cardiff University on 2 May 2019.
Prof Matt Smalley and Dr. Richard Clarkson presented their recent breast cancer research development supported by BCRA funding.
Through the support of Breast Cancer Research Aid, the Institute of Cancer Research has been able to make novel discoveries in the treatment of breast cancer.
ICR focuses on uncovering cancer drugs and combination therapies through ongoing research.
The research also intends to look into pathways of cancer development and ultimately what modifications lead to drug-resistance. Thus, guiding us toward better imaging modalities.
With the help of Breast Cancer Research Aid, our researchers get better equipped with the latest technology and cutting-edge infrastructure
Testimonial from ICR
"We are very grateful to Breast Cancer Research Aid for your support of The Royal Marsden’s C-TRAK trial, an innovative research project that has the potential to change the lives of women diagnosedwith triple-negativee breast cancer in the UK and worldwide. The Royal Marsden was founded thanks to contemporary philanthropists and your generosity is continuing this important tradition. Thank you for helping us to drive forward advances in breast cancer research and provide patients with the best quality of life".
I hope you are doing well.
Thank you to Breast Cancer Research Aid for your recent donation of £1,000 in support of The Institute of Cancer Research’s breast cancer research. We are delighted to have your continued and generous support.
I thought you would be interested to see the latest edition of the ICR’s newsletter, Search. On pages 16 & 17 there is a feature on the ICR’s discovery of the breast cancer susceptibility gene BRCA2.
With best wishes
Nicola Shaw | Trusts Fundraising Manager
The Institute of Cancer Research | 15 Cotswold Road | Belmont | Sutton | Surrey | SM2 5NG
Postal Address 123 Old Brompton Road, London, SW7 3RP
Making the discoveries that defeat cancer
The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP.
We are very grateful to Breast Cancer Research Aid for your support of The Royal Marsden’s C-TRAK trial,
an innovative research project that has the potential to change the lives of women diagnosed with triple
negative breast cancer in the UK and world-wide.
The Royal Marsden was founded thanks to contemporary philanthropists and your generosity is
continuing this important tradition. Thank you for helping us to drive forward advances in breast cancer
research and provide patients with the best quality of life.